Meeting the Challenges in Management of Sickle Cell Disease

To participate in this activity, please:

No longer a life-threatening disease, sickle cell disease (SCD) has become a chronic disease with life-threatening events that requires coordinated care by a multidisciplinary care team. Join Michael R. DeBaun, MD, MPH, and Collin Montgomery, APRN, as they discuss the acute and chronic complications experienced by individuals with SCD and the barriers they often encounter. The faculty offer real-world strategies for overcoming these barriers to improve the quality of life and other health outcomes of patients with SCD. Learn about 4 medications approved for treating acute and chronic complications of SCD and how to optimize their use. Case studies are utilized to share the faculty’s experience and to facilitate integration into clinical practice.

Course Credit:

1.25 AANP Contact Hours
1.25 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2021-03-31
Closes: 2022-03-31

Target Audience:

This activity was developed for pediatric and adult hematologists, hematology nurse practitioners, emergency physicians, primary care physicians, pediatricians and other clinicians involved in the management of patients with sickle cell disease.

This activity is supported by an independent educational grant from Novartis. This Program is supported by a grant from Global Blood Therapeutics, Inc. This activity is supported in part by a grant from bluebird, bio, Inc.
  • Michael R. DeBaun, MD, MPH

    Professor of Pediatrics and Medicine
    Vice Chair for Clinical and Translational Research
    J.C. Peterson Chair in Pediatric Pulmonology
    Director, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease
    Vanderbilt Children’s Hospital
    Nashville, Tennessee

  • Collin Montgomery, APRN

    APRN Coordinator, UAMS Adult Sickle Cell Program
    University of Arkansas for Medical Sciences
    Division of Hematology and Oncology
    Department of Internal Medicine
    UAMS Medical Center
    Little Rock, Arkansas

Learning Objectives

  • Describe the causes and consequences of increased morbidity and mortality associated with sickle cell disease (SCD)
  • Integrate key SCD management guideline recommendations into practice
  • Compare and contrast standard, new, and emerging therapies for SCD—including mechanisms of action, dosing, safety and efficacy
  • Employ communication and education strategies to help patients establish goals to improve their quality of life, prevent disease worsening, and have fewer/less severe symptoms

Faculty Disclosures

Michael R. DeBaun, MD, MPH

Advisory Board:  Global Blood Therapeutics – clinical area: randomized controlled trial

Steering Committee: Novartis – clinical area: priapism


Collin Montgomery, APRN

No relationships to disclose.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is designated for up to 1.25 contact hours. Program ID# 59010.

Additional Content Planners

Heather M. Jimenez, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

All members of the Eisenhower Health Education Committee have no relevant commercial relationships to disclose.